{"filings":[{"id":1691559,"accession_number":"0001035267-26-000047","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2026-07-16T20:05:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Surgical Q2 revenue $2.89B (+19% YoY); GAAP EPS $2.29, non-GAAP $2.80","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide procedures grew ~16% (da Vinci +15%, Ion +36%); 468 da Vinci systems placed (246 da Vinci 5).","GAAP net income $818M ($2.29/diluted share) vs $658M ($1.81) YoY; non-GAAP net income $1.00B ($2.80).","Q2 included $28M net benefit from IEEPA tariff refunds; repurchased 0.9M shares for $0.38B.","FY2026 guidance: da Vinci procedure growth ~13.5%-15.5% (closer to midpoint); non-GAAP gross margin 68%-69%.","Non-GAAP operating expense growth guided at 11%-13%; tariff impact estimated at 1% of revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":722996,"accession_number":"0001035267-26-000042","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2026-05-28T20:35:49+00:00","items":["5.02","9.01"],"status":"ready","headline":"Intuitive Surgical names Taylor Patton CCO, Henry Charlton moves to SVP Global Business Ops","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Taylor Patton promoted to Chief Commercial and Marketing Officer, effective July 1, 2026.","Henry Charlton transitions to SVP of Global Business Operations after serving as CCO.","Patton previously led Intuitive's Ion platform launch as Global SVP of Endoluminal.","Charlton has been with Intuitive since 2003; will support smooth transition.","Patton joins Executive Leadership team; Charlton will focus on global value generation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90740,"accession_number":"0001035267-26-000035","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"Intuitive Surgical boosts buyback to $5.0B; shareholders approve plan amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board increased stock repurchase authorization to $5.0B aggregate, including prior remaining balance.","Stockholders approved amendment to 2010 Incentive Award Plan, increasing authorized shares by 5M to 125.35M.","All 10 director nominees were elected at annual meeting; each received over 273M votes for.","Advisory say-on-pay passed with ~93.3% support (265M for, 17M against).","PricewaterhouseCoopers ratified as independent auditor for FY 2026 with ~98.6% of votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90739,"accession_number":"0001035267-26-000029","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Q1 rev $2.77B (+23%), EPS $2.50 non-GAAP; procedures +17%, da Vinci placements 431","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.77B (+23% YoY); GAAP EPS $2.28, non-GAAP EPS $2.50 (vs. $1.92/$1.81 prior year).","Worldwide procedures +17% YoY; da Vinci +16%, Ion +39%.","Placed 431 da Vinci systems (vs 367), including 232 da Vinci 5 (vs 147); installed base 11,395 (+12%).","Repurchased 2.3M shares for $1.1B in Q1; cash and investments $7.98B (down $1.05B).","FY2026 guidance: da Vinci procedure growth 13.5%-15.5%; non-GAAP gross margin 67.5%-68.5% (incl. 1% tariff impact)."],"consensus_eps_estimate":null,"consensus_eps_actual":2.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":2770800000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100505,"accession_number":"0001035267-26-000012","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Intuitive Surgical completes acquisition of European distributors, expands direct ops in 5 countries","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed March 1, 2026, of da Vinci and Ion distribution business from ab medica, Abex, Excelencia Robótica.","Direct operations begin in Italy, Spain, Portugal, Malta, and San Marino.","Approximately 250 employees join Intuitive's European team.","Combined installed base >470 da Vinci surgical systems in those countries as of Dec 31, 2025.","Ion endoluminal system launched in Italy and Spain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100504,"accession_number":"0001035267-26-000006","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Q4 revenue $2.87B (+19% YoY); non-GAAP EPS $2.53 vs $2.21; 2026 procedure growth guidance 13-15%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $2.87B (+19% YoY); GAAP net income $795M ($2.21 diluted EPS); non-GAAP net income $914M ($2.53 diluted EPS).","Worldwide da Vinci procedures +17%, Ion procedures +44% YoY; placed 532 da Vinci systems (303 da Vinci 5) and 42 Ion systems.","Installed base: 11,106 da Vinci systems (+12% YoY); 995 Ion systems (+24% YoY).","2026 outlook: da Vinci procedure growth 13-15%; non-GAAP gross margin 67-68% (includes ~1.2% tariff headwind).","Q4 included $70M contribution to Intuitive Foundation (vs $45M in Q4 2024)."],"consensus_eps_estimate":null,"consensus_eps_actual":7.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":10064700000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100503,"accession_number":"0001035267-26-000003","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Surgical Q4 2025 revenue $2.87B, up 19% YoY; procedures grow 18%","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Revenue $2.87B in Q4 (+19% YoY); full year $10.06B (+21%).","Worldwide da Vinci procedures +17% in Q4, +18% full year; Ion procedures +44% Q4, +51% FY.","Placed 532 da Vinci systems in Q4 (+8% YoY), including 303 da Vinci 5 systems (up from 174).","2026 da Vinci procedure growth guidance 13-15%.","Full year da Vinci procedures exceeded 3.15 million; U.S. general surgery +18%."],"consensus_eps_estimate":null,"consensus_eps_actual":7.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":10064700000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116828,"accession_number":"0001035267-25-000211","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Intuitive Surgical CDO Brian Miller transitions to Head of Digital and AI Strategy effective Jan 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brian E. Miller, Ph.D., will cease serving as Chief Digital Officer effective January 1, 2026.","He will assume a new role as Head of Digital and AI Strategy, no longer reporting to CEO.","Miller remains employed by Intuitive Surgical in a reduced executive capacity.","No replacement for CDO announced; the role appears to be eliminated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116827,"accession_number":"0001035267-25-000206","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Surgical Q3 revenue $2.51B (+23% YoY); EPS $1.95 GAAP / $2.40 non-GAAP; procedures +20%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide procedures grew ~20% YoY; da Vinci +19%, Ion +52%.","Revenue $2.51B (+23% YoY); GAAP net income $704M ($1.95/diluted share), non-GAAP $867M ($2.40).","Placed 427 da Vinci systems (240 da Vinci 5); installed base 10,763 (+13% YoY). Ion base 954 (+30%).","Repurchased 4.0M shares for $1.92B in Q3.","FY2025 guidance: procedure growth ~17-17.5%; non-GAAP gross margin 67-67.5% (incl. tariff impact ~0.7% of revenue)."],"consensus_eps_estimate":null,"consensus_eps_actual":5.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":7198500000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133271,"accession_number":"0001035267-25-000183","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Surgical Q2 revenue up 21% to $2.44B; non-GAAP EPS $2.19 vs $1.78","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.44B (+21% YoY); GAAP diluted EPS $1.81; non-GAAP diluted EPS $2.19 (vs $1.46/$1.78 last year).","da Vinci procedures up ~17%; placed 395 systems including 180 da Vinci 5 (vs 341/70). Installed base 10,488 (+14% YoY).","Full-year 2025 guidance: procedure growth 15.5%-17%; non-GAAP gross margin 66%-67% (includes ~1% tariff impact).","EU MDR certification and Japan clearance obtained for da Vinci 5 in July/June 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":3.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":4693400000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149914,"accession_number":"0001035267-25-000161","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Intuitive Surgical promotes President Dave Rosa to CEO effective July 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David J. Rosa promoted to CEO effective July 1, 2025; he previously served as President.","Current CEO Gary Guthart becomes Executive Chair; Board Chair Craig Barratt becomes Lead Independent Director.","Rosa's base salary increases from $825k to $925k; bonus target raised from 125% to 150% of salary.","Rosa receives RSUs valued at $4M and PSUs valued at $4M, vesting over 4 years and performance-based.","Guthart's base salary reduced to $700k; he will remain employee in senior advisory capacity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149913,"accession_number":"0001035267-25-000156","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"Intuitive Surgical boosts buyback to $4B; shareholders approve plan amendment increasing share reserve","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board increased stock repurchase authorization to $4.0B aggregate, including prior remaining amounts.","Shareholders approved amendment to 2010 Incentive Award Plan: shares increased from 115.35M to 120.35M, term extended to 2035.","All 11 director nominees elected, including Gary Guthart, Craig Barratt, and Amy Ladd.","Advisory vote on executive compensation passed (273.6M for); two shareholder proposals (compensation, golden parachutes) rejected.","Ratification of PricewaterhouseCoopers as independent auditor for FY2025 (315.8M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149912,"accession_number":"0001035267-25-000106","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Q1 revenue $2.25B, EPS $1.92; procedure volume +17%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.25B (+19% YoY); GAAP EPS $1.92, non-GAAP EPS $1.81.","da Vinci procedure volume +17% YoY; 367 systems placed (147 da Vinci 5).","Installed base 10,189 systems (+15% YoY).","FY25 outlook: procedure growth 15-17%; non-GAAP gross margin 65-66.5% (incl. ~1.7% tariff headwind).","Cash and investments $9.10B."],"consensus_eps_estimate":null,"consensus_eps_actual":1.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":2253400000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168932,"accession_number":"0001035267-25-000008","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Intuitive Q4 beats: rev $2.41B, adj EPS $2.21; buys Euro distributors for ~€321M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 da Vinci procedures grew ~18% YoY; 493 systems placed including 174 da Vinci 5.","Q4 GAAP EPS $1.88, non-GAAP EPS $2.21; revenue $2.41B (+25% YoY).","Acquisition of da Vinci/Ion distribution in Italy, Spain, Portugal, etc. for €290M upfront + €31M milestones; closing H1 2026.","2025 outlook: da Vinci procedure growth 13-16%, non-GAAP gross margin 67-68%.","Installed base grew 15% to 9,902 systems; cash and investments $8.83B."],"consensus_eps_estimate":null,"consensus_eps_actual":6.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":8352100000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168931,"accession_number":"0001035267-25-000005","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Q4 rev $2.41B (+25% YoY), procedures +18%; guides 2025 procedure growth 13-16%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 preliminary revenue $2.41B, up 25% YoY; full-year 2024 revenue $8.35B, up 17%.","Q4 da Vinci procedures grew ~18% YoY; full-year procedures up ~17% to 2,683,000.","493 da Vinci systems placed in Q4 (174 da Vinci 5), up 19% YoY; 1,526 in 2024, up 11%.","2025 procedure growth guidance of 13-16% vs 2024.","Q4 instruments & accessories revenue $1.41B (+23%), systems revenue $655M (+36%)."],"consensus_eps_estimate":null,"consensus_eps_actual":6.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":8352100000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168930,"accession_number":"0001035267-25-000002","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Intuitive Surgical promotes Samath to EVP/CFO and Charlton to EVP/Commercial","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jamie Samath promoted to EVP, CFO and Head of Business Technology effective January 1, 2025.","Samath's base salary raised from $605k to $683k; bonus target increased from 65% to 100% of base.","Henry Charlton promoted to EVP, Chief Commercial and Marketing Officer effective same date.","Charlton's base salary raised from $600k to $670k; bonus target increased from 65% to 100% of base."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186028,"accession_number":"0001035267-24-000244","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Surgical Q3 revenue $2.04B (+17% YoY); GAAP EPS $1.56, non-GAAP $1.84","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["da Vinci procedures grew 18% YoY; placed 379 systems including 110 da Vinci 5 units.","Revenue $2.04B; instruments/accessories +18% to $1.26B; systems revenue $445M.","GAAP net income $565M ($1.56/diluted share) vs $416M ($1.16) in Q3 2023.","Non-GAAP net income $669M ($1.84/diluted share) vs $524M ($1.46).","South Korea regulatory clearance for da Vinci 5 in multiple surgical specialties."],"consensus_eps_estimate":null,"consensus_eps_actual":4.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":5938600000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202607,"accession_number":"0001035267-24-000215","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Intuitive President David J. Rosa appointed to Board of Directors, effective July 24, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rosa has been Intuitive President since May 2023; manages core business operations including quality, regulatory, manufacturing, and commercial.","Board expanded from 11 to 12 directors; Rosa fills new seat, joining CEO Gary Guthart as the second executive on the board.","Rosa has over 27 years at Intuitive; also chairs Intuitive-Fosun joint venture board and serves on Kardium Inc. board.","No transactions requiring Item 404(a) disclosure were reported in connection with the appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202606,"accession_number":"0001035267-24-000203","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Surgical Q2 revenue $2.01B (+14% YoY), GAAP EPS $1.46, non-GAAP $1.78","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.01B (+14% YoY); GAAP net income $527M ($1.46 EPS), non-GAAP $641M ($1.78 EPS).","Worldwide da Vinci procedures grew ~17% vs Q2 2023; placed 341 systems (incl. 70 da Vinci 5).","Installed base grew 14% to 9,203 systems; instruments & accessories revenue $1.24B (+16%).","Cash and investments $7.68B, up $360M in quarter; no COVID disruption in H1 2024.","CEO cites healthy business, positive feedback on da Vinci 5 and adoption of SP and Ion."],"consensus_eps_estimate":null,"consensus_eps_actual":2.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":3900500000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218763,"accession_number":"0001035267-24-000171","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Intuitive Surgical shareholders approve all board nominees, equity plans; committee chairs appointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lewis Chew appointed Audit Committee Chair; Jami Dover Nachtsheim appointed Governance Committee Chair.","All 11 director nominees elected; advisory say-on-pay approved with ~93% support (269.5M for, 17.7M against).","Stockholders approved amended and restated 2010 Incentive Award Plan and 2000 Employee Stock Purchase Plan.","Shareholder proposal requesting racial/gender pay gap report rejected: 191.7M against vs 94.8M for.","Ratification of PricewaterhouseCoopers LLP as independent auditor for 2024 approved (313.0M for, 1.7M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218762,"accession_number":"0001035267-24-000133","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Q1 revenue $1.89B (+11% YoY), GAAP EPS $1.51, da Vinci procedures +16%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $1.89B (+11% YoY); GAAP EPS $1.51, non-GAAP EPS $1.50; procedure volume +16%.","Placed 313 da Vinci systems (8 da Vinci 5, 8 SP in Europe); installed base 8,887 (+14% YoY).","CE mark for da Vinci SP in Europe; FDA clearance for da Vinci 5; NMPA clearance for Ion in China.","Instruments & accessories revenue $1.16B (+18%); systems revenue $418M (slight decline).","Cash $7.32B; no COVID-19 procedure disruptions in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":1.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":1890600000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238664,"accession_number":"0001035267-24-000125","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intuitive announces FDA clearance of fifth-gen da Vinci 5 robotic system","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA 510(k) clearance obtained for da Vinci 5, Intuitive's next-generation multiport surgical robot.","System includes 150+ enhancements: force-sensing Force Feedback, improved 3D display, and 10,000x computing power vs. da Vinci Xi.","Force Feedback reduces force on tissue by up to 43% in preclinical trials; optional instruments cleared for most procedures.","Initial U.S. launch limited to development partners and mature robotic surgery programs before wider rollout.","Teleconference scheduled for March 18, 2024 to discuss features, benefits, and launch plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238663,"accession_number":"0001035267-24-000009","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2024-01-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Surgical Q4 2023 revenue $1.93B (+17% YoY), GAAP EPS $1.69, procedures up 21%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.93B (+17% vs $1.66B Q4 2022); GAAP net income $606M ($1.69/diluted share).","Non-GAAP net income $574M ($1.60/diluted share) vs $439M ($1.23) a year ago.","Worldwide da Vinci procedures grew ~21% YoY; placed 415 systems (vs 369).","Installed base 8,606 systems (+14% YoY); instruments revenue $1.14B (+22%).","CE mark obtained for da Vinci SP system in Europe; commercial rollout planned for 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":5.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":7124100000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238662,"accession_number":"0001035267-24-000006","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Surgical Q4 revenue $1.93B (+17% YoY); 2024 procedure growth guidance 13-16%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $1.93B (+17% YoY); full-year 2023 revenue $7.12B (+14% YoY).","Worldwide da Vinci procedures grew 21% in Q4 and 22% in full-year 2023.","Placed 415 da Vinci systems in Q4 (+12% YoY); 1,370 systems in 2023 (+8% YoY).","Instruments & accessories revenue up 22% in Q4 and full year to $1.14B and $4.28B.","Expects 2024 worldwide procedure growth of 13% to 16%."],"consensus_eps_estimate":null,"consensus_eps_actual":5.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":7124100000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256159,"accession_number":"0001035267-23-000203","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Intuitive Surgical appoints Sreelakshmi Kolli to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sreelakshmi Kolli appointed effective Oct 27, 2023, expanding board to 12 members.","Kolli is EVP and Chief Digital Officer at Align Technology; also on Zimmer Biomet board.","Annual cash retainer of $70,000 for non-employee director service, prorated until next annual meeting.","Initial grants of $70,000 in stock options and $70,000 in RSUs, vesting on first anniversary or next annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256158,"accession_number":"0001035267-23-000192","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2023-10-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Surgical Q3 revenue $1.74B (+12%), GAAP EPS $1.16, non-GAAP $1.46; procedures +19%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.74B, up 12% YoY; GAAP net income $416M ($1.16/diluted), up from $324M ($0.90) in Q3'22.","Non-GAAP net income $524M ($1.46/diluted), up from $429M ($1.19) in prior year.","Worldwide da Vinci procedures grew ~19% vs Q3'22; installed base 8,285 systems (+13% YoY).","Placed 312 da Vinci systems in Q3 (vs 305 in Q3'22), including 163 under operating leases.","Instruments & accessories revenue $1.07B (+23%), systems revenue $379M (-11% due to lease mix)."],"consensus_eps_estimate":null,"consensus_eps_actual":3.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":5195800000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273556,"accession_number":"0001035267-23-000155","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Surgical Q2 revenue $1.76B (+15% YoY), EPS $1.18, procedures +22%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.76B (+15% YoY); GAAP EPS $1.18 vs $0.85; non-GAAP EPS $1.42 vs $1.14.","Worldwide da Vinci procedure volume grew ~22% YoY; compound annual growth from Q2 2019 to Q2 2023 ~17%.","Placed 331 da Vinci systems (vs 279); installed base 8,042 systems (+13% YoY).","Instruments & accessories revenue $1.08B (+20%); systems revenue $393M.","Cash and investments $7.13B, increased $553M during quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":2.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":3452100000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290543,"accession_number":"0001035267-23-000142","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Intuitive Surgical promotes David J. Rosa to President; Guthart remains CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rosa promoted to President effective May 16, 2023; will lead product, digital, quality, regulatory, supply chain, manufacturing, and commercial teams.","Annual base salary increased from $652,468 to $700,000; bonus target raised from 100% to 120% of base.","Grants of $1.5M stock option, $1.5M RSUs, and $2M PSUs awarded under 2010 Incentive Award Plan.","Gary Guthart remains CEO; Bob DeSantis named EVP and Chief Strategy and Corporate Operations Officer.","Rosa has been with Intuitive for 27 years and previously served as EVP and Chief Strategy and Growth Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290542,"accession_number":"0001035267-23-000133","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Intuitive Surgical shareholders elect all 11 directors and approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected; top vote-getter Gary Guthart received ~281.3M for, ~1.57M against.","Advisory say-on-pay passed with 256.3M for (90.4% of votes cast excluding broker non-votes).","Annual frequency for advisory vote on exec compensation approved with 280.2M for 1-year option.","Ratification of PwC as auditor for FY2023 passed with 306.7M for, 1.2M against.","Shareholder proposal on pay equity disclosure rejected with 181.0M against vs 98.8M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290541,"accession_number":"0001035267-23-000087","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2023-04-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Surgical Q1 revenue $1.70B (+14% YoY), da Vinci procedures +26%, non-GAAP EPS $1.23","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.70B, up 14% YoY; constant currency growth of 17%.","GAAP diluted EPS $1.00 (flat); non-GAAP diluted EPS $1.23 vs $1.13.","da Vinci procedure volume grew ~26% YoY; placed 312 systems; installed base 7,779 (+12%).","Instruments & accessories revenue $986M (+22%); systems revenue $427M (flat).","European certification for Ion endoluminal system obtained; initial focus on UK market."],"consensus_eps_estimate":null,"consensus_eps_actual":1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":1696200000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311441,"accession_number":"0001035267-23-000006","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2023-01-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Q4 revenue $1.66B (+7%), GAAP EPS $0.91, non-GAAP $1.23; 18% procedure growth, $1B buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.66B (+7% YoY); GAAP net income $325M ($0.91/sh) vs $381M ($1.04/sh) in Q4 2021.","Non-GAAP net income $439M ($1.23/sh) vs $473M ($1.29/sh); global da Vinci procedures up 18% YoY.","Placed 369 da Vinci systems (-4% YoY); installed base 7,544 (+12%).","Repurchased $1B of common stock in Q4; cash & investments $6.74B.","COVID resurgence in China negatively impacted Q4 procedures; litigation charge of $21M."],"consensus_eps_estimate":null,"consensus_eps_actual":3.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":6222200000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311440,"accession_number":"0001035267-23-000003","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2023-01-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Q4 revenue $1.66B (+7% YoY); procedures +18%; 2023 guidance 12-16% growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $1.66B (up 7% YoY); FY22 revenue $6.22B (up 9% YoY).","Worldwide da Vinci procedures +18% in Q4 and FY22; 2023 growth guided at 12-16%.","Placed 369 systems in Q4 (down 4% YoY); FY22 placements 1,264 (down 6% YoY).","Instruments & accessories revenue $941M (+12% YoY); systems revenue $451M (-4% YoY).","COVID-19 resurgence in China negatively impacted Q4 procedure volumes."],"consensus_eps_estimate":null,"consensus_eps_actual":3.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":6222200000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330021,"accession_number":"0001035267-22-000176","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2022-10-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Intuitive Surgical enters $1B accelerated share repurchase agreement with Citibank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered $1B ASR with Citibank; initial delivery of ~3.6 million shares.","Final settlement expected last week of December 2022, may be accelerated.","Repurchase based on VWAP less discount; potential additional shares or cash at settlement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330020,"accession_number":"0001035267-22-000165","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2022-10-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Q3 revenue $1.56B up 11% YoY; GAAP EPS $0.90 vs $1.04","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide da Vinci procedures grew ~20% YoY; installed base 7,364 systems (+13%).","System placements of 305, down 9% from 336 in Q3 2021.","Non-GAAP EPS $1.19 flat YoY; GAAP net income $324M vs $381M.","Repurchased $1B of common stock in Q3 2022.","Japan cleared da Vinci SP for several surgical indications in September 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":2.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":4567200000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347584,"accession_number":"0001035267-22-000136","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Intuitive Surgical enters $1B accelerated share repurchase with Goldman Sachs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered ASR agreement with Goldman Sachs to repurchase $1 billion of common stock.","Initial payment of $1B; received ~3.5 million shares upfront.","Final settlement expected in ~3 months; may require additional shares or cash.","Repurchase based on volume-weighted average price during the period less a discount."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347583,"accession_number":"0001035267-22-000123","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2022-07-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q2 GAAP net income $308M ($0.85 EPS) down 40% YoY; revenue $1.52B up 4%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide da Vinci procedures grew ~14% YoY; system placements 279 (down 15%).","Instruments & accessories revenue $895M (+12%); systems revenue $375M (-15%).","Non-GAAP net income $415M ($1.14 per share) vs $475M ($1.30) in Q2 2021.","Repurchased $500M of common stock in Q2; Board increased buyback authorization to $3.5B.","Ended Q2 with $8.18B cash; cash decreased $226M due to buybacks and capex."],"consensus_eps_estimate":null,"consensus_eps_actual":1.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":3009800000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364074,"accession_number":"0001035267-22-000115","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2022-05-03T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"Intuitive Surgical Stockholders Approve Increase in Incentive Plan Shares to 110.35M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 2010 Incentive Award Plan amendment, increasing share reserve from 103.35M to 110.35M shares, extending term to 2032.","All 11 director nominees elected, including CEO Gary Guthart, with vote counts ranging from ~248.5M to ~287.3M for each.","Advisory vote on executive compensation passed with ~267.6M for (92.6% of votes cast).","Ratification of PricewaterhouseCoopers as auditor for 2022 passed with ~314.3M for (99.2%).","Amendment to incentive plan passed with ~180.2M for (62.4% of votes cast), despite significant opposition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364073,"accession_number":"0001035267-22-000081","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2022-04-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Surgical Q1 revenue $1.49B (+15%), GAAP EPS $1.00 vs $1.17 YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["da Vinci procedures grew ~19% YoY; compound annual growth from Q1 2019 was ~15%.","Placed 311 systems (+4% YoY); installed base reached 6,920 systems (+13% YoY).","GAAP net income $366M vs $426M YoY; non-GAAP net income $413M vs $427M.","Cash and investments $8.40B, down $218M in quarter on share repurchases and capex.","Company cited COVID resurgence as headwind but customer demand healthy per CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":1487700000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383804,"accession_number":"0001035267-22-000006","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2022-01-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Q4 revenue $1.55B (+17% YoY); da Vinci procedures +19%; GAAP EPS $1.04, non-GAAP $1.30","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $381M ($1.04/diluted share); non-GAAP net income $477M ($1.30/diluted share).","Worldwide da Vinci procedures increased ~19% vs Q4 2020; CAGR vs Q4 2019 was ~13%.","Shipped 385 systems (+18% YoY); installed base reached 6,730 systems (+12% YoY).","Instruments & accessories rev $843M (+13%); systems rev $470M (+28%); cash & investments $8.6B.","Q4 2021 COVID-19 resurgence impacted procedures; 2020 Q4 also disrupted by pandemic."],"consensus_eps_estimate":null,"consensus_eps_actual":4.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":5710100000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383803,"accession_number":"0001035267-22-000003","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2022-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Surgical Q4 revenue $1.55B (+17%), FY2021 $5.71B (+31%), da Vinci procedures +19% in Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue $1.55B (+17% YoY); FY2021 revenue $5.71B (+31% YoY).","da Vinci procedures grew ~19% in Q4, ~28% in 2021; 2022 guidance 11-15% growth.","Shipped 385 systems in Q4 (+18% YoY) and 1,347 in 2021 (+44% YoY).","Instruments & Accessories revenue $843M in Q4 (+13%); Systems $470M (+28%).","FDA cleared 8mm SureForm 30 Curved-Tip Stapler; $30M Intuitive Foundation contribution."],"consensus_eps_estimate":null,"consensus_eps_actual":4.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":5710100000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":401640,"accession_number":"0001035267-21-000174","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2021-10-19T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Intuitive Surgical Q3 rev $1.40B (+30% YoY), EPS $1.04; names Jamie Samath CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $1.40B (+30% YoY); GAAP net income $381M ($1.04 diluted EPS); non-GAAP $435M ($1.19 diluted EPS).","Worldwide da Vinci procedures up ~20% YoY; 336 systems shipped (+72% YoY); installed base 6,525 (+11%).","Leadership changes effective Jan 1, 2022: Jamie Samath promoted to CFO; Marshall Mohr to Global Business Services; Dave Rosa to Strategy & Growth; Henry Charlton to CCO.","Cash and investments $8.2B at quarter end; stock split approved (trading split-adjusted Oct 5)."],"consensus_eps_estimate":null,"consensus_eps_actual":3.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":4159400000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":420582,"accession_number":"0001035267-21-000170","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2021-09-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Intuitive Surgical shareholders approve 3-for-1 stock split; authorized shares doubled to 600M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Special meeting held Sep 20, 2021; proposal approved 103,018,171 for, 1,034,443 against, 120,412 abstain.","Authorized shares increased from 300M to 600M to effect the three-for-one stock split.","Split intended to make common stock more accessible to a broader investor base."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":420581,"accession_number":"0001035267-21-000144","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2021-08-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Intuitive Surgical announces 3-for-1 stock split, pending shareholder vote on Sept. 20","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved a 3-for-1 split via amendment to certificate of incorporation; authorized shares to increase from 300M to 600M.","Record date for split is Sept. 27, 2021; distribution date Oct. 4; trading on split-adjusted basis expected Oct. 5.","Outstanding equity awards (options, RSUs) will be proportionally adjusted; vesting schedules unchanged.","Company states split should not be interpreted as incremental confidence in future financial results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":420580,"accession_number":"0001035267-21-000115","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2021-07-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Surgical Q2 revenue up 72% to $1.46B; GAAP EPS $4.25, non-GAAP EPS $3.92; procedures up 68%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.46B (+72% YoY); procedure growth 68% YoY; compound annual growth 16.5% from Q2 2019.","GAAP net income $517M ($4.25 diluted); non-GAAP net income $477M ($3.92 diluted).","Shipped 328 da Vinci systems (+84% YoY); installed base 6,335 (+10% YoY).","Cash and investments $7.7B, up $504M during quarter; generated from operations.","Instruments/accessories revenue $796M (+73%); systems revenue $440M (+68%)."],"consensus_eps_estimate":null,"consensus_eps_actual":7.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":2756100000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}